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a b s t r a c t
MiR-221 was reported to be upregulated and play roles in tumorigenesis of hepatitis C virus (HCV) associated
hepatocellular carcinoma (HCC). However, the role of miR-221 in HCV infection remains unknown. In this
study, it was found that miR-221 was upregulated in serum of HCV chronic hepatitis patients and Huh7.5.1
cells infected with HCVcc. Further studies indicated that miR-221 mimic could accentuate anti-HCV effect of
IFN-α in HCVcc model, miR-221mimic could further repressed 10% HCV RNA expression and 35–42% HCV core
or NS5A protein expression in HCVcc infected Huh7.5.1 cells treated with 100 IU/mL IFN-α, and miR-221
inhibitor resulted in the reverse effects. Furthermore, two members of suppressor of cytokine signaling (SOCS)
family, SOCS1 and SOCS3, which are well established inhibitory factors on IFN/JAK/STAT pathway, were
identiﬁed as the targets of miR-221 and were involved in the effect of miR-221. In conclusion, miR-221 could
accentuate IFN's anti-HCV effect by targeting SOCS1 and SOCS3.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Hepatitis C virus (HCV) is a blood-transmitted human virus and
it is a global health problemwith estimated of 170 million infected
individuals worldwide (Chisari, 2005). Seventy percent of acute
infections are rapidly established as chronic infections, which is a
leading cause of liver cirrhosis and hepatocellular carcinoma (HCC)
(Bowen and Walker, 2005).
In the past decades, studies have focused on investigating the
genes and proteins underlying HCV infection, the host defenses and
the progression of HCC (Gale and Foy, 2005; Garaigorta and Chisari,
2009; Liu and Gale, 2010). Recently, an increasing number of reports
described a new class of small regulatory RNA molecules termed
microRNAs (miRNAs) that are implicated in the progression of
hepatitis virus associated HCC (Negrini et al., 2011; Zhang et al.,
2010; Braconi et al., 2010; Diaz et al., 2013) and in response to virus
infection (Berkhout and Jeang, 2007; Watanabe et al., 2007; Marquez
et al., 2010). Specially, miR-122 has been shown to intensify the
replication of HCV by targeting the viral 50 non-coding region (Jopling
et al., 2005). Moreover, the locked nucleic acid (LNA)—modiﬁed
oligonucleotide (SPC3649) complementary to miR-122 leads to long-
lasting suppression of HCV viremia, with no evidence of viral
resistance or side effects in HCV chronically infected chimpanzees
(Lanford et al., 2010). The use of an antisense oligonucleotide that
sequesters mature miR-122 in a highly stable heteroduplex, miravir-
sen, in patients with chronic HCV genotype 1 infection showed
prolonged dose-dependent reductions in HCV RNA levels without
evidence of viral resistance (Janssen et al., 2013). These ﬁndings
suggest miRNAs are involved in liver tumorigenesis at early stage of
HCV infection and have the potential to become novel drug targets in
virally induced infectious or malignant diseases.
MiR-221 has been reported in a variety of cancers including HCC
(Garofalo et al., 2012). MiR-221 is involved in liver ﬁbrosis and HCC
angiogenesis and tumorigenesis by regulating its target proteins (Park
et al., 2011; Gramantieri et al., 2009; Pineau et al., 2010; Fornari et al.,
2008; Ogawa et al., 2012; Santhekadur et al., 2012; Callegari et al.,
2012). MiR-221 regulates CDKN1C/p57 and CDKN1B/p27 expressions
(Park et al., 2011); miR-221 targets Bmf and correlates with tumor
multifocality (Gramantieri et al., 2009); overexpression of miR-221
contributes to tumorigenesis (Pineau et al., 2010); the knockdown of
miR-221 blocks hepatocellular carcinoma and promotes survival
(Fornari et al., 2008); miR-221 activates hepatic stellate cells and
contributes to liver ﬁbrosis (Ogawa et al., 2012); miR-221 is involved in
the promotion of tumor angiogenesis by staphylococcal nuclease
domain containing 1 (SND1) (Santhekadur et al., 2012); miR-221 is
found to promote liver tumorigenicity in transgenic mouse model
(Callegari et al., 2012). Although miR-221 has been reported to play
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.06.024
0042-6822/& 2014 Elsevier Inc. All rights reserved.
n Corresponding author. Tel./fax: þ86 21 81870990.
nn Corresponding author. Tel./fax: þ86 21 81870996.
E-mail addresses: wonwin29@126.com (W. Wang), hmren@yahoo.com (H. Ren).
1 These three authors contributed equally to this work.
Virology 462-463 (2014) 343–350
important roles in HCV associated HCC tumorigenesis, the mechanistic
details of direct role of miR-221 in the regulation of HCV replication
however remain unclear. In the present study, miR-221 was found to
accentuate IFN's effect of repressing HCV replication by targeting
suppressor of cytokine signaling 1(SOCS1) and suppressor of cytokine
signaling 3(SOCS3).
Results
MiR-221 is upregulated by HCV infection
In serum of HCV infected patients with chronic hepatitis,
miR-221 was upregulated around 4.5 folds in serum of patients
with CHC (n¼34) compared with healthy blood donors (n¼22)
(Fig. 1A). To verify whether the upregulation of miR-221 is
associated with HCV infection, the relative expression of miR-
221 in HCVcc infected Huh7.5.1 cells was evaluated. Seventy two
hours after HCVcc infection, miR-221 was upregulated around
5.3 folds in Huh7.5.1 cells (Fig. 1B). Huh7.5.1 cells infected with
HCVcc were harvested at different time points, and the relative
expressions of HCV RNA and miR-221 were determined by real-
time PCR. To conﬁrm the upregulation of miR-221 by HCVcc
infection, time and dose dependency assay were performed.
Intracellular HCV RNA increased rapidly and reached to a relative
plateau at day 3 post-infection, and miR-221 expression increased
to a relative stable level at day 3 post-infection (Fig. 1C). In
contrast, there were no signiﬁcant changes in expressions of
miR-221 in uninfected group throughout the experiment (data
not shown). In addition, Huh7.5.1 cells were infected with different
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Fig. 1. MiR-221 is upregulated by HCV infecton. (A) The expression of miR-221 in serum of HCV chronic hepatitis patients. (B) The expression of miR-221 in Huh7.5.1 cells
72 h after HCVcc infection. (C) Expressions of HCV RNA and miR-221 in Huh7.5.1 cells at the indicated time points post-infection. (D) Expressions of HCV RNA and miR-221 in
Huh7.5.1 cells after infection with different levels of HCVcc. Intracellular HCV RNA and miR-221 are analyzed by RT-PCR. GAPDH and U6 are used as an internal control.
Column, mean of three independent experiments; bars, SD; n, Po0.01, nn, Po0.001.
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amounts of HCV for 3 days. The expression of HCV RNA and
miR-122 in each group (105 IU/ml group, 106 IU/ml group and
107 IU/ml group) increased to different levels (Fig. 1D). These
results indicated that HCV infection could induce the upregulation
of miR-221.
MiR-221 accentuates IFN's repression of HCV replication
To investigate the possible role of miR-221 in HCV infection, the
effect of miR-221 on HCV replication was evaluated in Huh7.5.1
cells infected with HCVcc and transfected with or without, miR-
221 mimic, miR-221 inhibitor, mm-NC or mi-NC. The expression of
miR-221 was increased 23.6 folds in cells transfected with 20 nM
miR-221 mimic, but decreased 68.4% in cells transfected with
20 nM miR-221 inhibitor (Fig. 2A). By RT-PCR assay, 100 IU/ml
IFN-α could repress more than 80% HCV replication in HCVcc
infected Huh7.5.1 cells. In addition, HCV RNA expression was
further deceased by 43.6% by miR-221 mimic, but increased
36.5% by miR-221 inhibitor (Fig. 2B). However, miR-221 mimic or
inhibitor showed no effect on HCV RNA expression in HCVcc
infected Huh7.5.1 cells without IFN-α treatment (Fig. 2B). Similar
results were seen by Western blotting. The expressions of HCV
core and NS5A protein were further decreased 35% and 42%,
respectively, in miR-221 mimic transfected cells; but increased
105% and 123%, respectively, in miR-221 inhibitor transfected cells
only with IFN-α treatment (Fig. 2C). These results indicate that
miR-221 is most likely involved in the repression effect of IFN-α
signaling on HCV replication.
To verify the mechanism of miR-221, the effects of miR-221 on
IFN-α downstream signaling pathway were evaluated. In HCVcc
infected Huh7.5.1 cells, the induction of exogenous IFN-α upregu-
lated the phosphorylation of JAK1, STAT1 and STAT3 as expected.
In addition, miR-221 mimic further increased but miR-221 inhi-
bitor decreased the phosphorylation of JAK1, STAT1 and STAT3
(Fig. 3A, left panel). In addition, without HCVcc infection, miR-221
mimic also further increased and miR-221 inhibitor decreased the
phosphorylation of JAK1, STAT1 and STAT3 induced by IFN-α
(Fig. 3A, right panel). These results indicated that miR-221 could
upregulate IFN/JAK/STAT signaling pathway which is independent
on HCV infection.
A number of proteins, including IRF7, ISG15, OAS1 and PKR
induced by the JAK/STAT pathway play a role in the antiviral
responses of IFN-α. We directly tested whether miR-221 mimic
and miR-221 inhibitor could affect the expression of these ISGs. In
IFN-a treated Huh7.5.1 cells, all of these 4 ISGs mRNA expressions
were signiﬁcantly increased by RT-qPCR, miR-221 mimic could
further increase ISG15 and IRF7, but miR-21 inhibitor decreased
their mRNA levels, to 45.6-fold and 18.7-fold and 28.7-fold and
16.2-fold, respectively (Fig. 3B). Taken together, these ﬁndings
indicate that miR-221 increases the expression of several impor-
tant anti-HCV factors including ISG15 and IRF7 which correlates
with decreased HCV replication.
SOCS1 and SOCS3 are the targets of miR-221
It is generally accepted that miRNAs exert their function
through regulating the expression of their downstream target
genes. SOCS1 and SOCS3 were predicted as potential targets of
miR-221 by TargetScan and PicTar. The 30-UTR of SOCS1 and SOCS3
mRNA contained a complementary site for the seed region of miR-
221 (Fig. 4A). To validate whether SOCS1 and SOCS3 are the targets
of miR-221, 30UTR fragment of SOCS1 and SOCS3 containing miR-
221 binding sequence were subcloned downstream of a luciferase
reporter vector. In HEK293T cells cotransfected with the reporter
Fig. 2. MiR-221 represses HCV replication. (A) The expression of miR-221 in Huh7.5.1 cells with or without transfection of miR-221 mimic, miR-221 inhibitor or mm-NC,
mi-NC. (B) HCV RNA expression is further repressed by miR-221 in Huh7.5.1 cells infected with HCVcc under 100 IU/ml IFN-α treatment by quantitative RT-PCR. (C) HCV Core
and NS5A protein expressions are further repressed by miR-221 in Huh7.5.1 cells infected with HCVcc under 100 IU/ml IFN-α treatment by Western blotting. U6 and GAPDH
are used as an internal control. Column, mean of three independent experiments; bars, SD; *, Po0.01; **, Po0.001.
G. Xu et al. / Virology 462-463 (2014) 343–350 345
plasmids and miR-221 mimic, mutant miR-221 or mm-NC, the
luciferase activity of the reporter that contained SOCS1 and SOCS3
30-UTR was signiﬁcantly suppressed by miR-221 mimic, but the
luciferase activity of the reporter that contained SOCS1 and SOCS3
mutant 30-UTR remained no signiﬁcant difference (Fig. 4B). Using
mutant miR-221, the luciferase activity of the reporter that con-
tained mutant SOCS1 and SOCS3 30-UTR was signiﬁcantly sup-
pressed (Fig. 4B). The results indicated that miR-221 may suppress
gene expression through miR-221 binding sequence at the 30-UTR
of SOCS1 and SOCS3. Furthermore, transfection of miR-221 mimic
decreased SOCS1 and SOCS3 expressions and transfection of miR-
221 inhibitor increased SOCS1 and SOCS3 expressions in Huh7.5.1
cells at both mRNA (by qRT-PCR) and protein level (Western
blotting) (Fig. 4C and D), suggesting that SOCS1 and SOCS3
expressions could be inhibited by miR-221. Together, these results
showed that miR-221 could regulate the expressions of human
SOCS1 and SOCS3 by directly targeting the 30-UTR of SOCS1 and
SOCS3 mRNA.
MiR-221 is involved in IFN's repression on HCV replication by
targeting SOCS1 and SOCS3
To identify whether inhibition of SOCS1 and SOCS3, just like
miR-221 restoration, also resulted in HCV repression, the effects of
knockdown of SOCS1 and SOCS3 on HCV replication were exam-
ined. Seventy two hours after transfection with SOCS1, SOCS3
speciﬁc siRNAs or NC siRNA, the expressions of SOCS1 and SOCS3
were decreased at 48.3% and 81.3% respectively (Fig. 5A). The
knockdown of SOCS1 or SOCS3 upregulated the phosphorylation
of JAK1, STAT1 and STAT3 (Fig. 5A). Furthermore, knockdown of
both SOCS1 and SOCS3 enhanced the repression of HCV replication
by IFN-α (Fig. 5B), and miR-221 showed no further effect in such
SOCS1 or SOCS3 knockdown cells (Fig. 5B). These results indicate
that SOCS1 and SOCS3 are most likely involved in the effect of
miR-221 on IFN-α signaling.
Together with the above ﬁndings, it was concluded that miR-
221 rescue JAK/STAT signaling by targeting SOCS1 and SOCS3, and
rescued IFN/JAK/STAT signaling repress HCV replication more
efﬁciently, thus miR-221 accentuates anti-HCV activity of IFN-α
by targeting SOCS1 and SOCS3 (Fig. 5C).
Discussion
Altered miRNA expression during viral infections includes both
miRNAs that target viral sequences as well as miRNAs that target
host genes that inﬂuence the course of viral replication and
pathogenesis (Kumar, 2011). A number of miRNAs have been
reported to be involved in HCV infection. MiR-491 was involved
in regulation of HCV replication via the PI3 kinase/Akt pathway
(Ishida et al., 2011); miR-155 was found to be associated with HCV
infection (Bala et al., 2012); and let-7b can also regulate HCV
replication (Cheng et al., 2012).
In the present study, we demonstrated miR-221 could help to
repress HCV replication, which might provide new insights into
the mechanisms underlying HCV infection, but also raise a doubt
on the exact functions of miR-221. As reported by previous studies,
miR-221 is regarded as an oncogene which could enhance tumor-
igenesis (Janssen et al., 2013; Garofalo et al., 2012; Park et al., 2011;
Gramantieri et al., 2009; Pineau et al., 2010; Fornari et al., 2008;
Ogawa et al., 2012). Our ﬁndings suggest that miRNAs might play
dual roles in HCV infection. Research on miR-122 support such a
hypothesis. On the one hand, miR-122 enhances the replication,
translation and infectious virus production of HCV (Chang et al.,
2008; Jangra et al., 2010; Roberts et al., 2011); overexpression of
miR-122 even supports the entire HCV life cycle in HepG2 cells
(Narbus et al., 2011). On the other hand, miR-122 plays an
Fig. 3. MiR-221 upregulates IFN-α induced JAK/STAT pathway. (A) MiR-221 rescued JAK/STAT signaling pathway. The key molecular of JAK/STAT pathway including p-JAK1,
p-STAT1 and p-STAT3 are deregulated in IFN-α treated Huh7.5.1 cells transfected with miR-221 mimic or miR-221 inhibitor. (B) ISGs including ISG15 and IRF7 are further
upregulated by miR-221 in IFN-α treated Huh7.5.1 cells. GAPDH is used as an internal control. Column, mean of three independent experiments; bars, SD; *Po0.01.
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inhibitory effect on HCC tumorigenesis since it was found that
miR-122 suppresses cell proliferation and induces cell apoptosis in
HCC by targeting Wnt/β-catenin pathway (Xu et al., 2012),
inhibiting tumorigenicity (Bai et al., 2009; Hsu et al., 2012).
Moreover, miR-122 was reported to repress HBV transcription in
a p53-dependent manner (Wang et al., 2012; Fan et al., 2011),
which could suggest a possible virus type dependent role of
miRNAs. As Sendi (2012) discussed, miR-122 might play the
dual role of in viral hepatitis, and therapeutic applications of
miR-122 might differ based on the underlying disease. Thus,
miRNAs could play different roles in viral infection and virus-
associated tumorigenesis.
As the IFN system represents an integral part of the mamma-
lian innate immunity, it is likely that miRNAs might either target
pattern recognition receptors and signaling components involved
in the IFN induction after pathogen recognition, or alter expression
of proteins involved in the IFN response such as the JAK/STAT
pathway. Several cellular miRNAs that are induced during viral
infection were reported to negatively modulate the IFN pathway.
MiR-26a, miR-34a, miR-145, and let-7b were proved to be IFN-β
inducible and directly regulated IFN-β expression during infection
as a negative feedback loop (Witwer et al., 2010). MiR-146 limits
interleukin-1 receptor associated kinase 1 (IRAK1) and TNF recep-
tor associated factor 6 (TRAF6) expression and directly attenuated
transcriptional induction via the IFN-α/β receptor by limiting
expression of STAT1 (Taganov et al., 2006; Tang et al., 2009).
Inducible expression of miR-155 was observed during both bacter-
ial and viral infections, as well as after exposure of cells to
proinﬂammatory cytokines such as IFN-β, IFN-γ, or tumor necrosis
factor alpha (TNF-α) (O’Connell et al., 2007).
It is generally accepted that miRNAs exert their function
through regulating the expression of their target genes. No
candidate related to IFN/JAK/STAT pathway was predicted as the
target of miR-221 by TargetScan and PicTar. Interesting, SOCS1 and
SOCS3 were predicted as the targets of miR-221. SOCS family is a
mainly negative regulator of JAK/STAT signaling. So far, 8 members
of the SOCS family have been identiﬁed, termed SOCS1 to SOCS-7
and CIS (Yoshimura, 2009). Both SOCS1 and SOCS3 can inhibit JAK
tyrosine kinase activity directly through their kinase inhibitory
regions (KIR) (Yasukawa et al., 1999). For HCV infection, SOCS1
suppression was associated with abnormal B cell activation
(Moorman et al., 2009); HCV core protein exerts an inhibitory
effect on SOCS1 expression (Miyoshi et al., 2005); and increased
expression of SOCS3 was associated with non-response to antiviral
therapy (Walsh et al., 2006). Furthermore, SOCS1 has been
reported to be a target of miR-155 and miR-221 (Cardoso et al.,
2012; Lu et al., 2011), while SOCS3 is the target of miR-203 in
gingival epithelial cells (Moffatt and Lamont, 2011). We identiﬁed
SOCS1 and SOCS3 as the targets of miR-221, which might provide
a further understanding on the regulation of SOCS1 and SOCS3.
Fig. 4. SOCS1 and SOCS3 are the targets of miR-221. (A) The putative miR-221 binding sequence in the 30-UTR of SOCS1 and SOCS3 mRNA. (B) Suppressed luciferase activity
of wild type 30UTR of SOCS1 and SOCS3 by miR-221 mimic. HEK293T cells are cotransfected pMIR-SOCS1-30UTR or pMIR-SOCS3-30UTR, and miR-221 mimic or mm-NC, mi-
NC. Fireﬂy luciferase activity of each sample is measured 48 h after transfection and normalized to Renilla luciferase activity. (C and D) The expressions of SOCS1 and SOCS3
mRNA (C) and protein (D) are regulated by miR-221. The expressions of SOCS1 and SOCS3 in Huh7.5.1 cells are analyzed 48 h after transfection with miR-221 mimic, miR-221
inhibitor or mm-NC, mi-NC by quantitative RT-PCR (C) or Western blotting (D). GAPDH is used as an internal control. Column, mean of three independent experiments;
bars, SD; *, Po0.01; **, Po0.001.
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In summary, our ﬁndings suggest miR-221 could regulate SOCS1/
SOCS3 and functions as an IFN enhancer in HCV infection. Herein,
we provide characterization of potential miR-221 target genes and
broaden the understanding of IFN stimulated gene regulation.
Materials and methods
Serum specimens, cell lines and reagents
Serum samples used in this study were collected from 34 HCV
infected patients with chronic hepatitis (Qujing, Yunnan province,
China). The diagnosis was determined by physical examination,
blood chemistry, and magnetic resonance imaging. No patient had
received chemotherapy. Additional samples were collected from
22 blood donors in Shanghai Changhai Hospital, in which standard
markers for HBV or HCV infection tested negative. Clinical and
pathological information was extracted from the patients' medical
charts and pathology reports (Table 1). Written consent for tissue
donation (for research purposes) was obtained from the patients
before serum collection and the protocol was approved by the
Institutional Review Board of Second Military Medical University.
The samples were frozen in liquid nitrogen and stored at 80 1C
until use.
Human embryonic kidney cells (HEK293T) and human HCC
cells lines Huh7.5.1 were cultured in DMEM medium plus 10% FBS
(Invitrogen, Carlsbad, CA, USA) at 37 1C in a humidiﬁed atmo-
sphere containing 5% CO2.
SOCS1 siRNA, SOCS3 siRNA and nonrelative siRNAwere purchased
from Santa Cluz Biotechnology (Santa Cruz, CA, USA); Interferon-
alpha (IFN-α) was purchased from Piscataway (Middlesex County, NJ,
USA); miR-221 mimic, mutant miR-221 mimic and nonrelative mimic
control RNA (mm-NC), miR-221 inhibitor and nonrelative inhibitor
control RNA (mi-NC) were purchased from Ribobio (Gangzhou,
China).
Generation of HCV viral stocks and infection of Huh7.5.1 cells
Infectious HCV in cell culture (HCVcc) was generated as described
previously (Lindenbach et al., 2005). Brieﬂy, plasmid pFLJ6/JFH1,
containing the full-length chimeric genomic cDNA for HCV J6 and
JFH-1was linearized and used as the template for transcription using
an in vitro MEGAscript kit (Promega). The in vitro-transcribed RNA
was delivered to Huh7.5.1 cells by electroporation. Viral stocks were
obtained by harvesting the culture supernatants on days 8 to 18 after
transfection and aliquoted for storage at 80 1C. The titer of viral stock
was determined in Huh7.5.1 cells by immunostaining as described
Fig. 5. SOCS1 and SOCS3 are involved in the repression of HCV replication by miR-221. (A) MiR-221 as well as SOCS1 and SOCS3 knockdown could rescue JAK/STAT signaling
pathway. The phosphorylation of key molecular of JAK/STAT pathway is deregulated in HCVcc infected Huh7.5.1 (with IFN-α) cells transfected with miR-221 mimic, miR-221
inhibitor or SOCS1 siRNA, SOCS3 siRNA. GAPDH is used as an internal control. (B) SOCS1 and SOCS3 knockdown downregulated HCV protein expression in HCVcc infected
Huh7.5.1 cells as miR-221 do. U6 is used as an internal control. (C) Schematic representation of the main ﬁndings in this study. Column, mean of three independent
experiments; bars, SD; *, Po0.01; **, Po0.001.
Table 1
Proﬁles of patients.
HCV patients (n¼34) Blood donors (n¼22) Ref. value
Age (years) 45711.7 46.5714.6
Male/female 9/13 11/20
HCV RNA
(copies/ml)
3.9879.6105 o500 o500
HBV DNA
(copies/ml)
o500 o500 o500
ALT 68.9759.9 22.379.9 5–40 IU/L
AST 77.7774.4 18.776.8 8–40 IU/L
GGT 69.1744.6 16.575.1 7–32 IU/L
ALB 46.372.57 36.2572.22 35–55 g/L
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previously (Lindenbach et al., 2005). Brieﬂy, HCVcc-infected cells were
washed, ﬁxed with cold methanol, probed with anti-HCV-positive
sera, washed, and probed with FITC-conjugated anti-human IgG
(Jackson ImmunoResearch, UK). Finally, the cells were labeled with
DAPI and images were acquired using a ﬂuorescence microscope
(IX81; Olympus, Tokyo, Japan). Stained foci were counted in quad-
ruplicate wells, and the virus titer of focus-forming units (ffu)/mL was
calculated.
Huh7.5.1 cells were seeded in a 24-well plate, and following an
overnight culture, a 50 uL HCVcc supernatant with 5105 ffu/mL
was added to each well for 5 h, and then supplemented with fresh
culture medium after washing with culture medium 5 times. For
miRNA or IFN treatment, 20 nM miR-221 mimic or inhibitor was
transfected into the cells at day 1 after HCVcc infection; then,
100 IU/mL IFN-α was added or not to the cells at day 2; ﬁnally,
HCV protein was detected by western blotting with relevant
antibodies and the HCV RNA was determined by quantitative
RT-PCR at day 3 or day 4.
Quantitative real time PCR
Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturers' recommendations. An
A260 nm/A280 nm ratio of 1.9 and a 28S/18S ratio of 1.8 were
minimum requirements for the following PCR. Total RNA (2 μg)
was reverse transcribed with the SuperScript III First-Strand Synth-
esis System with speciﬁc reverse primers or Oligo (dT) (Invitrogen).
The primers (Table S1) and SYBR RT-PCR kit (Takara, Shiga, Japan)
were used for ampliﬁcation. Reactions were incubated in a 96-well
optical plate at 95 1C for 5 min, followed by 40 cycles at 95 1C for 15 s
and 60 1C for 1 min. PCR reactions were run on a StepOne Plus real-
time PCR machine (Applied Biosystems, Foster City, CA, USA) and the
data were analyzed by SDS v2.3 software. U6 and GAPDH were used
as the control.
Plasmids construction
The fragments of 30-UTR of SOCS1 (790–1203nt, Genbank
accession NM_003745) and SOCS3 (2102–2621nt, Genbank accession
NM_003955) containing the two putative miR-221 binding sequences
(1140–1147nt and 2381–2386nt) were ampliﬁed with the primers
SOCS1-UTR and SOCS3-UTR (Table S1). The PCR product was cloned
into pMIR-REPORT™miRNA Expression Reporter Vector (Ambion, TX,
USA), termed as pMIR3-SOCS1-30UTR and pMIR-SOCS3-30UTR. The
plasmids which carried the mutated sequence in the complementary
sites for the seed region of miR-221 (Fig. 2A) were generated based on
pMIR3-SOCS1-30UTR and pMIR-SOCS3-30UTR plasmid by MutanBEST
Kit (Takara Bio, Shiga, JP), termed as pMIR3-SOCS1-mut-30UTR and
pMIR-SOCS3-mut-30UTR. These plasmids were conﬁrmed by sequen-
cing analyses.
Transfection
The transfections were carried out using FuGene HD transfec-
tion reagent (Roche, Indianapolis, IN, USA) following the manu-
facturer's protocol. In brief, 2104 Huh7.5.1 cells or 5104
HEK293T cells in 24-well plates were transfected with indicated
plasmids, miRNA or siRNA, and collected 24–48 h after transfec-
tion for assay.
Dual-luciferase reporter assay
HEK293T cells seeded in 24-well plates in triplicate were cotrans-
fected with pMIR-SOCS1-30UTR, pMIR-SOCS3-30UTR, pMIR3-SOCS1-
mut-30UTR or pMIR-SOCS3-mut-30UTR and miRNA-221 mimic,
mutant miR-221 mimic or mm-NC by using FuGene HD transfection
reagent. The pRL-TK (Promega) was also transfected as a normalization
control. Cells were collected 48 h after transfection, and luciferase
activity was measured using a dual-luciferase reporter assay kit
(Promega) and recorded by multi-plate reader (Synergy 2, BioTek).
Western blotting
Protein extracts from Huh7.5.1 cells were prepared by a modiﬁed
RIPA buffer with 0.5% sodium dodecyl sulfate (SDS) in the presence of
proteinase inhibitor cocktail (Complete mini, Roche), 25 mg protein of
cells were electrophoresed in 10% SDS-PAGE mini gels and transferred
onto PVDF membranes (Immobilon P-SQ, Millipore, Billerica, MA, USA).
After blocking with 5% nonfat milk, the membranes were incubated
with speciﬁc primary antibodies at 4 1C overnight, followed by
incubation with HRP-conjugated goat anti-rabbit or goat anti-mouse
antibody (1:10000 dilution, KPL, Gaithersburg, MA,USA) for 1 h at
room temperature. Finally, signals were developed with Super Signal
West Pico chemoluminescent substrate (Pierce), visualized by the
Gene Gnome HR Image Capture System (Syngene, Frederick, MD, USA)
and analyzed by Gene tools (Syngene). The primary antibodies used
were: HCV core and HCV NS5A (Thermo Fisher, Waltham, MA USA),
JAK1, STAT1, STAT3, SOCS1, SOCS3, pJAK1, pSTAT1, pSTAT1 rabbit
polyconal antibody (SAB, College Park, MD,USA) and GAPDH mouse
monoclonal antibody (ImmunoGen, shanghai, China).
Prediction of miRNAs targets
TargetScan (http://www.targetscan.org/) and PicTar (http://pic
tar.mdc-berlin.de/) programs were used to investigate the target
genes of miRNAs and the conserved sites bound by the seed region
of miR-221.
Statistical analysis
Data are presented as mean7SD. Comparisons were made by
using a two-tailed t test or one-way ANOVA for experiments with
more than two subgroups. Po0.01 was considered statistically
signiﬁcant.
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